Organovo is a biotechnology business based in the US. Organovo shares (ONVO) are listed on the NASDAQ and all prices are listed in US Dollars. Organovo employs 20 staff and has a trailing 12-month revenue of around $73,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.54 |
|---|---|
| 52-week range | $0.50 - $2.05 |
| 50-day moving average | $0.63 |
| 200-day moving average | $0.95 |
| Wall St. target price | $6.10 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.38 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.542 from 2024-09-06
| 1 week (2024-08-30) | -6.55% |
|---|---|
| 1 month (2024-08-07) | -1.02% |
| 3 months (2024-06-07) | -43.55% |
| 6 months (2024-03-07) | -46.34% |
| 1 year (2023-09-07) | -49.81% |
|---|---|
| 2 years (2022-09-07) | -77.03% |
| 3 years (2021-09-07) | 7.79 |
| 5 years (2019-09-06) | 5.274 |
| Revenue TTM | $73,000 |
|---|---|
| Gross profit TTM | $-8,515,000 |
| Return on assets TTM | -73.67% |
| Return on equity TTM | -151.72% |
| Profit margin | 0% |
| Book value | $0.46 |
| Market Capitalization | $8.9 million |
TTM: trailing 12 months
We're not expecting Organovo to pay a dividend over the next 12 months.
Organovo's shares were split on a 1:20 basis on 18 August 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Organovo shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Organovo shares which in turn could have impacted Organovo's share price.
Over the last 12 months, Organovo's shares have ranged in value from as little as $0.5 up to $2.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organovo's is 0.613. This would suggest that Organovo's shares are less volatile than average (for this exchange).
Organovo Holdings, Inc. , a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3 clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus on non-alcoholic steatohepatitis and primary biliary cholangitis. It has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.